Table 4 The incidence of paradoxical BP rises
Outcome | No. of SRs | No. of original studies | No. of cases/controls | Follow-up range (weeks) | Estimate (95%CI) | P-value |
|---|---|---|---|---|---|---|
Paradoxical blood pressure rise: ΔmsDBP> 5 mmHg | ||||||
 aliskiren vs placebo | 1 | 4 | 2110/902 | 8 | 0.27 [0.20–0.37] | < 0.00001 |
 aliskiren vs ARBs | 1 | 4 | 2110/701 | 4–9 | 0.86 [0.55–1.36] | 0.53 |
 aliskiren vs ramipril | 1 | 2 | 2110/617 | 9–26 | 1.19 [0.69–2.04] | 0.53 |
 aliskiren vs HCT | 1 | 1 | 2110/547 | 52 | 1.20 [0.68–2.13] | 0.52 |
ΔmsDBP> 10 mmHg | ||||||
 aliskiren vs placebo | 1 | 4 | 2110/902 | 8 | 0.27 [0.15–0.48] | < 0.00001 |
 aliskiren vs ARBs | 1 | 4 | 2110/701 | 4–9 | 0.57 [0.27–1.20] | 0.14 |
 aliskiren vs ramipril | 1 | 2 | 2110/617 | 9–26 | 0.93 [0.37–2.31] | 0.87 |
 aliskiren vs HCT | 1 | 1 | 2110/547 | 52 | 0.70 [0.30–1.67] | 0.42 |
 ΔmsSBP> 10 mmHg |  |  | ||||
 aliskiren vs placebo | 1 | 4 | 2110/902 | 8 | 0.31 [0.24–0.41] | < 0.00001 |
 aliskiren vs ARBs | 1 | 4 | 2110/701 | 4–9 | 0.97 [0.64–1.48] | 0.9 |
 aliskiren vs ramipril | 1 | 2 | 2110/617 | 9–26 | 0.69 [0.47–1.01] | 0.05 |
 aliskiren vs HCT | 1 | 1 | 2110/547 | 52 | 0.89 [0.57–1.38] | 0.59 |
ΔmsSBP> 20 mmHg | ||||||
 aliskiren vs placebo | 1 | 4 | 2110/902 | 8 | 0.40 [0.24–0.67] | 0.0005 |
 aliskiren vs ARBs | 1 | 4 | 2110/701 | 4–9 | 1.50 [0.62–3.61] | 0.37 |
 aliskiren vs ramipril | 1 | 2 | 2110/617 | 9–26 | 0.66 [0.34–1.29] | 0.22 |
 aliskiren vs HCT | 1 | 1 | 2110/547 | 52 | 0.87 [0.40–1.92] | 0.74 |